Critical IllnessNCT07761832
Hemoglobin Trends as a Predictor of Outcomes in Critically Ill Patients (The TRENT-ICU Study)
An observational study of Critical Illness and Anemia, run by Hospital H+ Queretaro at 1 site in Mexico.
Trial summary
The goal of this observational study is to evaluate if early absolute hemoglobin decline (during the first 24 hours of admission) can predict prolonged intensive care unit stay (8 days or more) and in-hospital mortality in critically ill adult patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Critical Illness, Anemia
- What is being tested?
- Early Absolute Hemoglobin Decline
- How many people
- 128 participants
- Where
- 1 siteMexico
- Study dates
- 31 Jul 2026to 31 Jul 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: dult patients admitted to the Intensive Care Unit at Hospital H+ Querétaro, Mexico, between January 2024 and January 2026, who required an ICU stay of more than 48 hours and had serial hemoglobin measurements during routine medical care.
Who may be able to join
- Adult patients (aged 18 years or older) admitted to the Intensive Care Unit (ICU) between January 2024 and January 2026.
- ICU length of stay greater than 48 hours.
- At least two hemoglobin determinations obtained with an interval of approximately 24 hours apart during routine medical care.
Who cannot join
- Massive bleeding upon ICU admission.
- Massive transfusion protocol activation.
- Pregnancy.
- Hemoglobinopathies.
- Active hemolytic anemia.
- Medical records with insufficient information for analysis.
Trial locations and contacts
1 site in 1 country.
Mexico1 site
Hospital H+ Querétaro, Santiago de Querétaro, Querétaro
Querétaro City, Querétaro, 76000
About this study
Official title: The TRENT-ICU Study (Transfusion Threshold Based on Hemoglobin Trends): Hemoglobin Drop Rate as a Predictor of Adverse Clinical Outcomes in Critically Ill Patients
The goal of this observational study is to evaluate if early absolute hemoglobin decline (during the first 24 hours of admission) can predict prolonged intensive care unit stay (8 days or more) and in-hospital mortality in critically ill adult patients.
The main questions it aims to answer are:
Read more
Does absolute hemoglobin decline during the first 24 hours of admission independently predict prolonged intensive care unit stay in critically ill adult patients?
Does absolute hemoglobin decline during the first 24 hours of admission independently predict in-hospital mortality in critically ill adult patients?
Participants will:
Have their routine clinical and laboratory data reviewed retrospectively from their electronic health records (including baseline hemoglobin and a second hemoglobin determination approximately 24 hours after admission). No additional interventions or extra blood draws will be performed beyond routine clinical care.
- Conditions
- Critical Illness, Anemia
- Being tested
- Early Absolute Hemoglobin Decline
- Keywords
- critical care, Hemoglobins, Blood Transfusion, Prognosis, Intensive Care Units
- Medical subject headings
- Critical Illness, Anemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Early Absolute Hemoglobin DeclineOther
Measurement of the absolute difference in hemoglobin concentration (g/dL) between baseline ICU admission and approximately 24 hours post-admission. Data was collected retrospectively from electronic health records.
| Study group | Role | What they receive |
|---|---|---|
| Critically Ill Adult Patients | Adult patients admitted to the intensive care unit with an ICU stay of more than 48 hours and at least two hemoglobin determinations obtained approximately 24 hours apart during routine care. Receives: Other: Early Absolute Hemoglobin Decline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prolonged Intensive Care Unit Stay
Incidence of prolonged intensive care unit (ICU) length of stay, defined a priori as an ICU stay equal to or greater than 8 days.
Measured: From ICU admission up to 28 days
Secondary outcomes (1)
In-Hospital Mortality
Incidence of all-cause mortality recorded at hospital discharge.
Measured: From ICU admission up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2026
- Study start31 Jul 2026
- Primary completion31 Jul 2026
- Study completion31 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Critical IllnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 128 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital H+ Queretaro
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jose J Zaragoza, MD MSc, Hospital H+ Queretaro
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07761832
- Sponsor's protocol ID
- CEI2026-30/04/V1
- Status last verified
- Aug 2026
- First submitted
- 3 Aug 2026
- Last updated
- 12 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The TRENT-ICU Study (Transfusion Threshold Based on Hemoglobin Trends): Hemoglobin Drop Rate as a Predictor of Adverse Clinical Outcomes in Critically Ill Patients
- ClinicalTrials.gov ID
- NCT07761832
- Acronym / sponsor ID
- CEI2026-30/04/V1
- Conditions
- Critical Illness, Anemia
- Keywords
- critical care, Hemoglobins, Blood Transfusion, Prognosis, Intensive Care Units
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 128 participants (actual)
- Lead sponsor
- Hospital H+ QueretaroUniversity, hospital or other
- Study start
- 31 Jul 2026 (actual)
- Primary completion
- 31 Jul 2026 (actual)
- Study completion
- 31 Jul 2026 (actual)
- First posted
- 12 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate if early absolute hemoglobin decline (during the first 24 hours of admission) can predict prolonged intensive care unit stay (8 days or more) and in-hospital mortality in critically ill adult patients.
The main questions it aims to answer are:
Does absolute hemoglobin decline during the first 24 hours of admission independently predict prolonged intensive care unit stay in critically ill adult patients?
Does absolute hemoglobin decline during the first 24 hours of admission independently predict in-hospital mortality in critically ill adult patients?
Participants will:
Have their routine clinical and laboratory data reviewed retrospectively from their electronic health records (including baseline hemoglobin and a second hemoglobin determination approximately 24 hours after admission). No additional interventions or extra blood draws will be performed beyond routine clinical care.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Critically Ill Adult Patients | – | Other: Early Absolute Hemoglobin DeclineAdult patients admitted to the intensive care unit with an ICU stay of more than 48 hours and at least two hemoglobin determinations obtained approximately 24 hours apart during routine care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- dult patients admitted to the Intensive Care Unit at Hospital H+ Querétaro, Mexico, between January 2024 and January 2026, who required an ICU stay of more than 48 hours and had serial hemoglobin measurements during routine medical care.
Key inclusion criteria (3 listed)
- Adult patients (aged 18 years or older) admitted to the Intensive Care Unit (ICU) between January 2024 and January 2026.
- ICU length of stay greater than 48 hours.
- At least two hemoglobin determinations obtained with an interval of approximately 24 hours apart during routine medical care.
Key exclusion criteria (6 listed)
- Massive bleeding upon ICU admission.
- Massive transfusion protocol activation.
- Pregnancy.
- Hemoglobinopathies.
- Active hemolytic anemia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Early Absolute Hemoglobin DeclineMeasurement of the absolute difference in hemoglobin concentration (g/dL) between baseline ICU admission and approximately 24 hours post-admission. Data was collected retrospectively from electronic health records. | Other | Critically Ill Adult Patients |
Primary outcome
Prolonged Intensive Care Unit Stay
Time frame: From ICU admission up to 28 days
Incidence of prolonged intensive care unit (ICU) length of stay, defined a priori as an ICU stay equal to or greater than 8 days.
1 secondary outcome
In-Hospital Mortality
Time frame: From ICU admission up to 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2026.
Related trials for Critical Illness
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Recruiting
Development and Preliminary Validation of Intelligent Video Laryngoscope for Emergency Use
Critically Ill Patients Requiring Mechanical Ventilation
Active, not recruiting
Weighted Blankets for Agitation in Adults in the Intensive Care Unit
Psychomotor Agitation, Critical Illness
Not yet recruitingObservational study
Core Competencies in General Intensive Care Ultrasound (GenIUS): a Delphi Study
Critical Illness, Ultrasound
RecruitingObservational study
Predicting Extubation Failure Using Machine Learning
Extubation Failure, Critical Illness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Critical Illness and Anemia, run by Hospital H+ Queretaro at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prolonged Intensive Care Unit Stay (time frame: From ICU admission up to 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.